Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy

Combination venetoclax plus ibrutinib for the treatment of mantle cell lymphoma (MCL) has demonstrated efficacy in the relapsed or refractory setting; however, the long-term impact on patient immunology is unknown. In this study, changes in immune subsets of MCL patients treated with combination ven...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood Adv
Autors principals: Davis, Joanne E., Handunnetti, Sasanka M., Ludford-Menting, Mandy, Sharpe, Chia, Blombery, Piers, Anderson, Mary Ann, Roberts, Andrew W., Seymour, John F., Tam, Constantine S., Ritchie, David S., Koldej, Rachel M.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2020
Matèries:
Immunobiology and Immunotherapy
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7556128/
https://ncbi.nlm.nih.gov/pubmed/33031542
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002810
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars